Test Drive Our New Site! We have some improvements in the works that we're excited for you to experience. Click here to try our new, faster, mobile friendly beta site. We will be maintaining our current version of the site thru mid 2025, so you can switch back as our improvements continue.
Legislation Quick Search
12/09/2024 06:28 AM
Pennsylvania House of Representatives
https://www.legis.state.pa.us/cfdocs/Legis/CSM/showMemoPublic.cfm?chamber=H&SPick=20170&cosponId=23836
Share:
Home / House Co-Sponsorship Memoranda

House Co-Sponsorship Memoranda

Subscribe to PaLegis Notifications
NEW!

Subscribe to receive notifications of new Co-Sponsorship Memos circulated

By Member | By Date | Keyword Search


House of Representatives
Session of 2017 - 2018 Regular Session

MEMORANDUM

Posted: May 5, 2017 11:04 AM
From: Representative Frank Burns
To: All House members
Subject: Resolution Urging Congress to Approve the STOP Act
 
In the near future, I intend to introduce a resolution urging Congress to pass the Synthetic Trafficking and Overdose Prevention (STOP) Act.

The United States is facing an epidemic of drug overdose deaths. Fentanyl, a deadly synthetic opioid often made in Chinese laboratories, is entering the United States through the U.S. mail because of a loophole in federal shipping law. This drug, which can be 40 times more potent than heroin, can kill a person with only a pinch.

Unlike private parcel carriers, such as Fed Ex, the U.S. Postal Service does not require electronic customs data – such as a package’s origin, destination and contents – to be sent in advance by the nation of origin. The STOP Act would close this loophole in federal law by requiring this vital data to be sent electronically in advance for packages coming through the U.S. mail. This would allow customs officials and Drug Enforcement Administration (DEA) agents to seize packages of illegal drugs, preventing them from reaching American consumers.

Please join me in urging Congress to pass the STOP Act so that we can reduce the influx of foreign-made synthetic drugs.




Introduced as HR325